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Abstract 
Background: Chlamydia is a bacterial infection that has long plagued humanity as the most commonly contracted 
STD and is caused by Chlamydia trachomatis. With the emergence of HIV/AIDS, sexually transmitted diseases have 
also re-emerged as a grave public health problem, particularly in developing countries. Updated Information about 
the relative frequencies in developing countries is sparse. This study aims at establishing the relative occurrence of 
chlamydia using real time PCR technique in the Vhembe District of South Africa where reports on the prevalence of 
chlamydia are not available.
Methods: A total of 243 Urine samples were collected from patients attending different ARV clinics in the Vhembe 
District and genomic DNA was purified using blood genomic DNA kit from Sigma-Aldrich. Real-Time PCR protocol 
targeting the 16S rRNA gene of C. trachomatis was used to confirm the presence of chlamydia among these patients. 
Demographic information as well as clinical data was collected as well.
Results: Of all the participants, 70.4 % were females. The age varied from 19 to 72 years. The overall prevalence of 
chlamydia was 32.1 %. The prevalence was significantly higher among females (39.2 %) compared to males (15.5 %) 
patients (P = 0.001) and was highest among pregnant women followed by patients who had reported any allergic 
reaction. Among the HIV positive patients, the prevalence was higher among those who were not taking ARV (38.1 %) 
compared to those who were taking them (28.5 %). The age group within which the highest prevalence was found 
was between 26–45 years.
Conclusions: The present study shows a high prevalence of chlamydia among HIV and AIDS patients in the Vhembe 
District emphasizing the need to enhance STI control and particularly chlamydia among all young people. The 
particularly high prevalence of chlamydia among pregnant women is of great concern as this predisposes them to 
complications, while allergy migh predispose people to chlamydia infections. Further studies are needed in the gen-
eral population both HIV positive and HIV negative persons to further determine the impact of these infections in the 
community.
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Background
With the appearance of HIV/AIDS, sexually transmitted 
diseases (STDs) have re-emerged as a grave public health 
problem, particularly in developing countries. There is 
strong evidence showing that the presence of genital 
ulcer disease and of some non-ulcerative STDs enhances 
the transmission of HIV [1]. There are more than 20 
types of STIs of which genital chlamydia and gonorrhea 
are the most prevalent throughout the world [2]. Chla-
mydia is also known as the silent STI due to its lack of 
symptoms in infected individuals particularly females. 
Chlamydia infection can lead to serious sequelae such as 
pelvic inflammatory diseases (PID), tubal factor infertil-
ity, ectopic pregnancy and chronic pelvis pain in women 
[3]. In men chlamydia leads to non gonococcal urethri-
tis (NGU), infection of the epididymis which is called 
epididymitis or the inflammation of the rectum known 
as proctitis [3]. Understanding the epidemiology of chla-
mydia is therefore the first step towards its control.
The prevalence of Chlamydia varies significantly 
between regions and countries. Studies conducted in 
Kenya, Zimbabwe, Nigeria and South Africa, have shown 
that the prevalence of C. trachomatis varied between 6 
and 56 % in these countries with most studies reporting 
prevalence of about 18 % [4–7]. In South Africa specifi-
cally, most studies were conducted using very specialized 
group of patients mostly all from one gendre like make 
only or female only samples [8, 9]. The Vhembe District 
is an immediate neighbor to the Mopani District where a 
new serotype of C. trachomatis was discovered although 
no studies have been conducted in the Vhembe District 
[10]. The primary prevention of chlamydia in the form of 
health education and secondary prevention through early 
diagnosis and treatment are important chlamydia control 
strategies [11]. Also, the improvement in management 
of STI’s can reduce the incidence of HIV infection in the 
general population [12]. C. trachomatis infection can be 
effectively cured with antibiotics such as azithromycin or 
ofloxacin once it is detected, for pregnant women eryth-
romycin or amoxicillin is recommended [13, 14].
Various methodologies can be used to detect C. tra-
chomatis [15]. Cell culture is considered as the gold 
standard in the diagnosis of C. trachomatis however the 
rapid evolution of the DNA amplification techniques 
(Polymerase chain reaction for example) is leading to the 
re-evaluations of this standard by the scientific commu-
nity [16]. Recently a technological innovation that came 
from PCR namely real time PCR has become more com-
mon for clinical diagnostics because it is run in a closed 
system and it has the ability to generate both qualitative 
and quantitative results [17]. Their main advantages are 
the possibility of quantification, along with greater sen-
sitivity, precision and accuracy as well as faster analysis 
making this technique superior to the other methods 
[18]. Hence this study aims at establishing the relative 
occurrence of chlamydia using real time PCR technique 
in the Vhembe District of South Africa where reports on 
the prevalence of chlamydia are not available.
Methods
Ethical clearance
The study was approved by the University of Venda 
Health and Ethics Committee and the Limpopo depart-
ment of health in Polokwane. Ethical clearance was also 
obtained from the hospitals where the samples were col-
lected. The objectives of the study were clearly explained 
to the patients as well as their rights to withdraw anytime 
and confidentiality. Those who agreed to participate in 
the research were requested to sign a consent form and 
complete the questionnaire with the help of a researcher 
in order to obtain socio-demographic information as well 
as data about previous sexual experience and the human 
experimentation guidelines were followed.
Sample collection and processing
Patients attending the HIV clinics in three major hospi-
tals in the Vhembe District including Elim, Tshilidzini 
and Donald Fraser hospitals as well as students attend-
ing the University of Venda HIV clinic for HIV testing 
and counseling were recruited in the study. All patients 
presenting at the above mentioned clinics between April 
and November 2010, were invited to participate in the 
study. The main reasons for these patients visiting the 
clinic were generally to get HIV care which include get-
ting their medication, a follow up visit to check for CD4 
count etc.… Urine samples were collected from the study 
participants who had agreed to take part in the study and 
were labeled with the patient’s code, sex, age and the col-
lection date. The samples were taken to the University of 
Venda Microbiology laboratory in cooler boxes with ice 
within 4  h of collection for analysis. Upon arrival, sam-
ples were centrifuged and the pellet was kept at −20 °C 
for further analysis.
DNA extraction
Genomic DNA was purified from urine samples using the 
commercially available blood genomic DNA extraction 
kit from Sigma Aldrich following the instructions from 
the manufacturer. The extracted DNA was then stored at 
−20 °C for further analysis.
Quantitative real‑time PCR
Genomic DNA extracted from the urine samples was 
used in a real-time PCR protocol using the primers pre-
viously described targeting the 16S ribosomal RNA of 
chlamydia with SYBR-Green-490 (Roche Diagnostics) 
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[16]. The reaction was performed in light cycler 480 
from Roche Diagnostics. The results were analyzed 
with a user-defined threshold of 200 PCR Baseline Sub-
tracted Curve-fit Relative Fluorescence Units (CF RFU). 
The level of positivity of the samples was then indicated 
by the cycle threshold (Ct) values, which represent the 
number of cycles necessary for the samples to cross the 
threshold: the smaller it is, the more DNA is in the sam-
ples. All runs included at least two negative controls and 
one positive control.
Statistical analysis
The analysis was conducted using the statistical pack-
age for social sciences (SPSS) program, version 17.1 with 
the fisher Chi square test and the difference between two 
variables was considered significant if the P value was less 
than 0.05. Different analysis including the student t test, 
the multivariate analysis correcting for confounders such 
as HIV status, the age of the participants, and the preg-
nancy status. A regression analysis was also conducted 
to evaluate the potential correlation between chlamydia 
infections and the different symptoms reported by the 
patients. In preparation of the regression model a uni-
variate analysis was conducted and the variables that had 
a P value of 0.1 or less, were retained for the construc-
tion of the regression model. Of all the variables, gender, 
pregnancy, fever and abortion were the variables that 
remained. Taking specific ARVs particulary zidovudine, 
tenofovir and stavudine was associated with a reduction 
on the prevalence of chlamydia. Following the selection 
using the univariate model, the variables were taken out 
of the model in s stepwise protocol and a linear regres-
sion was built taking into consideration all the variable 
that had some impact on the prevalence so as gender, 
fever, or abortion. Pregnancy was also an important 
factor.
Results
Distribution of chlamydia in the study population based 
on demographic characteristics and HIV status
Following amplification, the amplification and melt-
ing curves were generated by the Light Cycler 480 II as 
showed in Fig.  1. The patients were from different hos-
pitals and a clinic in the University of Venda (Univen). 
Of the 243 samples collected from as many patients, 78 
(32.1 %) were positive for chlamydia. The highest preva-
lence was found among students in the University with 
37.5 %. Female patients had the highest prevalence 39.2 % 
than males 15.5 % and the difference was statistically sig-
nificant (P = 0.001). Based on the marital status, widowed 
patients were the most infected with 46.7  % prevalence 
and the least infected were the singles with 27.5 %. Most 
people who were infected were between 25–45 years the 
least infected were 24  years and younger but the differ-
ence was not significant (P =  0.313). The patients’ HIV 
status did not seem to have an impact on the prevalence 
of chlamydia in the study sample although only eight HIV 
negative patients were tested. However, ARV treatment 
seemed to have a positive impact. In fact among the HIV 
positive, those who were not taking ARV’s had the high-
est prevalence 38.1 % than those who were taking them 
28.5 %. The results are presented on Table 1. The effects 
of the different antiretroviral drugs were evaluated on 
the occurrence of chlamydia. However, none of the drugs 
used had a significant impact on chlamydia (Table  2). 
Pregnant women had the highest prevalence of chla-
mydia compared to men and non-pregnant women and 
the difference was statistically significant (Table 3).
Impact of education and income status of patients on the 
prevalence of chlamydia
Based on education level and income of the household 
head, participants who indicated that they had an income 
of less than Rands 1000 per month appeared to be slightly 
higher prevalence of chlamydia (35.4  %) compared to 
those who had a higher salary (31.3 %). However, the dif-
ference was not statistically significant (P = 0.425). Most 
of the participants who had more than six dependents 
were more infected (35.4 %) compared to those who had 
between two and three dependents. Participants who 
went to secondary school were more infected (35.9  %) 
than those who went only to primary school (26.6 %). The 
results are indicated on Table 4.
Prevalence of chlamydia in relation to other symptoms 
experienced by the patients
In relation to the symptoms reported by the patients at 
the time of sample collection, chlamydia was detected 
most among patients who reported to have had STI’s 
with 26.0  %, vision problems with 32.6  %, sores on lips 
with 31.4 %, rash in genitals with 29.6 % and blind spot 
with 30.8 % (Table 5). The level of CD4 count as well as 
the viral load did not seem to affect the prevalence of 
chlamydia in the study population. Of all the conditions 
reported by the patients only alergy was significantly 
statistically associated with high prevalence of chla-
mydia (Table 5). This association persisted even after the 
data was segregated by gender. More male patients with 
allergy had chlamydia compared to males who did not 
report any allergy while females who reported any type of 
allergy were significantly more infected with chlamydia.
Prevalence of chlamydia in relation to the sexual behavior 
of the participants
Patients were asked in the questionnaires about their 
sexual behavior, this included the age at first sexual 
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experience, number of partners since first sexual expe-
rience, number of partners in the previous year and 
condom use. Patients who indicated that they had their 
first sex at an earlier age (between 12 and 15 years) had 
the highest prevalence (43.8  %). Patients who indicated 
that they had 1–4 partners since their first sexual expe-
rience where more infected (37.2  %) while those who 
indicated that they had more than 10 partners were 
the least infected (30.0  %). Patients, who had only one 
sexual partner in the previous year, were mostly infected 
(38.6  %) more than those who had 5 or more partners 
(28.6  %). People who indicated that they use condoms 
sometimes were more infected (44.7  %) than those 
who never use condoms (30.8 %) and those who always 
use it (28.9  %), but the difference was not significant 
(P = 0.262). The results are recorded in Table 6.
Fig 1 Amplification and melt curves obtained from the Light Cycler 480 II after real time PCR amplification of Chlamydia trachomatis DNA from the 
urine samples obtained from HIV positive and HIV negative patients visiting HIV care centres. a shows the amplification curves and b shows the 
melting curve analysis. The minor picks appearing at around 74 °C on the melting curves are probably due to the primer dimers
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Discussion
Chlamydia has been identified as an accelerator in the 
transmission and acquisition of HIV [19]. Most women 
and about half of men with chlamydia do not experience 
symptoms [20]. Since symptoms may not be present, 
the only way to know if a person who may be at risk, is 
infected with chlamydia is to be tested. In the present 
study, 243 urine samples were collected and tested by 
real time PCR. The overall prevalence of chlamydia in the 
present study is higher compared to those described in 
Table 1 Distribution of chlamydia in the study population by origin, age, gender and marital status
Variables Characteristics Total (N) Chlamydia positive  
N (%)
Statistics (Chi square  
and P value)
OR (odd ratio), 95 % CI  
(confidence interval)
Origin Elim 50 16 (32.0) χ2 = 0.00, P = 0.987 OR = 0.994, 95 % CI 0.0511–1.937
Tshilidzini 66 18 (27.3) χ2 = 0.968, P = 0.325 OR = 0.731, 95 % CI 0.38–1.35
Donald Fraser 119 41 (34.50) χ2 = 0.593, P = 0.441 OR = 1.23, 95 % CI 0.721–2.12
Univen 8 3 (37.5) χ2 = 0.111, P = 0.739 OR = 1.28, 95 % CI 0.29–5.49
Gender Female 171 67 (39.2) χ2 = 12.888, P = 0.001 OR = 3.514, 95 %CI 1.723–7.16
Male 71 11 (15.5)
Marital status Single 102 28 (27.5) χ2 = 3.99, P = 0.174 OR = 0.681, 95 % CI 0.391–1.187
Married 90 29 (32.2) χ2 = 0.00, P = 0.998 OR = 0.999, 95 % CI 0.572–1.746
Divorced 20 7 (35.0) χ2 = 0.077, P = 0.782 OR = 1.145, 95 %CI 0.438–2.994
Widowed 30 14 (46.7) χ2 = 3.267, P = 0.071 OR = 2.023, 95 % CI 0.932–4.392
Age groups 19–24 5 5 (20) χ2 = 2.112, P = 0.146 OR = 0.476, 95 % CI 0.171–1.320
25–45 135 48 (35.6) χ2 = 1.015, P = 0.314 OR = 1.332, 95 % CI 0.762–2.327
Above 45 74 24 (32.4) χ2 = 0.111, P = 0.916 OR = 0.969, 95 % CI 0.538–1.744
HIV Status HIV negative 8 3 (37.5) χ2 = 0.111, P = 0.739 OR = 0.918, 95 % CI 0.533–1.581
HIV positive 75 (31.9)
ARV Taking ARVs 154 43 (28.5) χ2 = 2.989, P = 0.130 OR = 0.647, 95 % CI 0.368–0.138
Not taking ARVs 84 32 (38.1)
Table 2 Occurrence of Chlamydia in a HIV population in relation to antiretroviral treatment




OR (odd ratio and 95 % 
confidence interval)
Not on ARV 84 32 (38.1) χ2 = 2.365, P = 0.124 OR 0.649, 95 % CI 0.374–1.228
On ARV 133 37 (27.8)
Zidovudine 12 6 (50) χ2 = 3.158, P = 0.076 OR 2.871, 95 % CI 0.861–9.562
Efavirenz 114 29 (25.4) χ2 = 2.784, P = 0.095 OR 0.426, 95 % CI 0.154–1.184
Lamivudine 129 36 (27.9) χ2 = 0.043, P = 0.836 OR: 0.774, 95 % CI 0.068–8.804
Tenofovir 42 11 (26.2) χ2 = 0.103, P = 0.748 OR 0.873, 95 % CI 0.383–1.993
Nevirapine 15 7 (46.7) χ2 = 2.914, P = 0.088 OR 0.426, 95 % CI 0.154–1.184
Stavudine 81 23 (28.4) χ2 = 0.014, P = 0.906 OR 1.048, 95 % CI 0.479–2.291
Table 3 Occurrence of chlamydia in the study population in relation to gender and pregnancy
Population Count Chlamydia  
positive (%)
Statistics (χ2, P value) OR (odd ratio and 95 % 
confidence interval)
Males 65 10 (15.4) χ2 = 12.88, P = 0.0001 OR 3.514, 95 % CI 1.723–7.165
Non-pregnant females 136 48 (35.3) χ2 = 3.376, P = 0.066 OR 2.095, 95 % CI 0.943–4.658
Pregnant females 30 16 (53.3) χ2 = 7.289, P = 0.007 OR 2.837, 95 % CI 1.302–6.186
Total 231 74 (32) χ2 = 7.183, P = 0.007 OR 2.818, 95 % CI 1.292–6.144
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other parts of South Africa even when similar popula-
tion (HIV positive) was used [21]. The prevalence of C. 
trachomatis was significantly higher in female patients 
(39.2 %) than in male patients (15.5 %) (P = 0.001). This 
could be due to chlamydia being asymptomatic in most 
cases particularly in females who therefore do not test 
and get treated. Similar results were obtained in a study 
on chlamydia prevalence in the general population in 
Netherlands were the prevalence was high in females 
than males [22]. Another study in Estonia found a high 
prevalence of 48.0 % in females than 32.0 % in males [23].
In Tanzania a study on the prevalence of HIV and C. 
trachomatis infection in 15–19-year olds in rural Tan-
zania found a prevalence of 2.4  % in females and 1.0  % 
in males. However other studies have shown a non-
significant difference between males and females [24]. 
For example a study in the United States on gender and 
age disparities in the prevalence of chlamydia infection 
among sexually active adults found that the observed dif-
ference in CT prevalence between females and males was 
not statistically significant (1.6 vs. 1.7 %) with the P value 
of 0.8 [25]. In high risk groups, chlamydial infection was 
found to be correlating with various socio-demographic 
characteristics, such as low education or being single. 
These associations are far less significant in the general 
population and tend to incorrectly classify many women 
at high risk of chlamydial infection, and therefore reduc-
tion in screening effectiveness [26].
In the present study, we found that widowed and 
divorced individuals had more CT infections compared 
to unmarried people. This situation is contrary to those 
described by other authors who found higher preva-
lence among single people compared to married people. 
A study by Kolvstad and his colleagues showed a higher 
prevalence of CT among single women (6.6  %) com-
pared to married women (0 %) [27]. However, a study in 
Jos, Nigeria among gynecologic clinic attendees found 
a higher prevalence of chlamydia in married women 
(38.41  %) compared to single women (17.07  %) and the 
divorced (0.61 %) [28]. In our study, a higher prevalence 
was observed among widowed patients (46.7 %) although 
the difference was not statistically significant (P = 0.262). 
These differences could be due to different popula-
tions dynamics in these countries, as well as the type of 
study population used. In another study, younger age, 
living alone or with persons other than partners/family 
members, engaging in unprotected vaginal intercourse 
(UVI) and having other STIs seemed to be associated 
with higher risk of CT infection [29]. Similarly, being 
divorced/widowed and working in middle/low-level ven-
ues were identified as additional risk factors for other 
STI’s such as gonorrhea.
Younger patient’s age has been associated with greater 
risk of chlamydia [30], because the cervix of teenage girls 
and young women is not fully matured and is probably 
more susceptible to infection, they are at particularly hi 
particularly high risk for infection if they are sexually 
active. Previous studies have demonstrated that C. tra-
chomatis infection is most common in people aged less 
than 25  years, with rates decreasing thereafter [31, 32]. 
In the present study, the prevalence was found to be 
high among people aged between 25–45  years (35.6  %). 
Similar results have been reported by previous studies in 
the African continent. For example, a high prevalence of 
43.9  % was reported in people of between 26–30  years 
in a study on the prevalence of chlamydia in patients 
attending gynecological clinics in South Eastern Nigeria 
[33]. A previous study in Mpumalanga Province found 
a high prevalence of (47.9  %) in male and (52.8  %) in 
female miners particularly those who were aged between 
46–50 years old [34].
In the present study, out of 235 HIV positive patients 
a 31.9  % prevalence was found. There were only 8 HIV 
negative patients, among whom 3 (37.5  %) were chla-
mydia positive. This could mean that the prevalence of 
chlamydia is not always associated with the reported HIV 
Table 4 Impact of socio-economic status of patients on the prevalence of chlamydia
Variables Characteristics Total (N) Positive N (%) Statistics
Income range less than 1000 Yes 96 34 (35.4) χ2 = 0.425, P = 0.515, OR = 1.204, 95 % CI 0.68–2.103
No 131 41 (31.3)
Number of dependents 1–3 dependents 87 26 (29.9) χ2 = 0.474, P = 0.491, OR = 0.816, 95 % CI 0.457–1.456
4–6 dependents 98 33 (33.7) χ2 = 0.093, P = 0.760, OR 1.093, 95 % CI 0.622–1.915
7–13 38 13 (34.2) χ2 = 0.093, P = 0.760, OR = 1.092, 95 % CI 0.522–2.283
Education Primary school 64 17 (26.6) χ2 = 1.533, P = 0.216, OR = 0.670, 95 % CI 0.355–1.266
Secondary school 128 46 (35.9) χ2 = 1.259, P = 0.262, OR = 1.367, 95 % CI 0.0.791–2.364
Tertiary school 20 6 (30.0) χ2 = 0.076, P = 0.782, OR = 0.869, 95 % CI 0.321–2.356
No education 26 9 (34.6) χ2 = 0.045, P = 0.832, OR = 1.097, 95 % CI 0.465–2.586
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Table 5 Prevalence of chlamydia in relation to the symptoms experienced by the patients
Characteristic Total Positive N (%) Statistics: χ2, P value OR, 95 % CI (odd ratio, 
95 % confidence interval)
Pain (general body pain)
 No 127 40 (31.5) χ2 = 0.646, P = 0.412 OR 1.265, 95 % CI 0.712–2.24
 Yes 87 32 (36.5)
Fever
 No 151 54 (35.8) χ2 = 1.029, P = 0.310 OR 0.719, 95 % CI 0.37–1.36
 Yes 63 18 (28.6)
Current chest pain
 No 194 58 (29.9) χ2 = 2.440, P = 0.118 OR 1.675, 95 % CI 0.87–3.21
 Yes 48 20 (41.7)
Allergy (any type of allergy)
 No 180 49 (27.2) χ2 = 6.841, P = 0.009 OR 2.202, 95 % CI 1.21–4.05
 Yes 62 28 (45.2)
Sores in genitals
 No 220 73 (33.2) χ2 = 1.251, P = 0.263 OR 0.559, 95 % CI 0.20–1.56
 Yes 23 5 (21.7)
Sores on lips
 No 208 67 (32.2) χ2 = 0.008, P = 0.927 OR 0.965, 95 % CI 0.44–2.08
 Yes 35 11 (31.4)
Genital warts
 No 212 71 (33.5) χ2 = 1.477, p = 0.224 OR 0.579, 95 % CI 0.23–1.41
 Yes 31 7 (22.6)
Rash in genitals
 No 150 45 (30) χ2 = 0.001, P = 0.969 OR 0.982, 95 % CI 0.40–2.41
 Yes 27 8 (29.6)
Mouth thrush last 3 months
 No 213 67 (31.5) χ2 = 0.490, P = 0.484 OR 1.332, 95 % CI 0.59–2.97
 Yes 29 11 (37.9)
Vision problem
 No 156 49  (31.4) χ2 = 0.034, P = 0.854 OR 1.054, 95 % CI 0.60–1.85
 Yes 86 28 (32.6)
Blurry vision
 No 41 16 (39) χ2 = 1.962, P = 0.165 OR 0.521, 95 % CI 0.20–1.31
 Yes 44 11 (25.0)
Blind spot
 No 72 23 (31.9) χ2 = 0.007, P = 0.933 OR 0.947, 95 % CI 0.26–3.39
 Yes 13 4 (30.8)
STD (general STI symptoms)
 No 191 64 (33.5) χ2 = 1.027, P = 0.311 OR 697, 95 % CI 0.34–1.40
 Yes 50 13 (26.0)
Diabetes
 No 237 78 (32.9) χ2 = 2.908, P = 0.088 OR 0.671, 95 % CI 0.61–0.733
 Yes 6 0 (0.0)
Hypertension
 No 233 74 (31.8) χ2 = 0.299, P = 0.585 OR 1.432, 95 % CI 0.39–5.22
 Yes 10 4 (40.0)
Epilepsy
 No 241 77 (32) χ2 = 0.296, P = 0.586 OR 2.13, 95 % CI 0.130–34.50
 Yes 2 1 (50)
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status. Similar results were obtained in the Mopani Dis-
trict South Africa in a study on prevalence of chlamydia 
and gonorrhea among HIV infected women in rural 
Mopani District [35]. The use of ARV also appeared to 
have effects on the infection rate because the percent-
age was high in HIV patients who were not taking ARV’s 
(38.1 %) than those who were taking it (28.5 %), therefore 
antiretroviral therapy could be helpful in reducing the 
risks and sequelae of chlamydia infection.
Socio-economical status of study participants has 
often been cited as risk factor for the occurrence of sev-
eral diseases. In our study, we found that the prevalence 
of CT was higher among people who admitted to having 
an income of less than 1000 Rands per month (35.4  %) 
although the difference was not significant (P =  0.425). 
This correlates with a study that was conducted in the 
United States by Klovstad et al. [27], where the percent-
age in people who were unemployed was higher com-
pared to those who were employed but also the difference 
was not significant. In our study a prevalence of 35.9 % 
was obtained among people who only studied until sec-
ondary school although the difference was not significant 
with other educational levels. Beydoun and colleagues 
[25] reported a higher prevalence in people who stud-
ied until high school only (4.8 %) compared to those who 
studied further until tertiary (0.8  %) and the difference 
was significant (P = 0.004).
People who had their first sexual intercourse at an early 
age were at higher risk of infection. We found the high-
est prevalence of chlamydia among people who started 
being sexually active between 12–15  years (43.8  %) 
although this difference was not statistically significant 
(P = 0.153). A study in Belgium focusing on chlamydial 
opportunistic screening in general practice found a sig-
nificant difference (P = 0.008) between people who had 
their first sexual intercourse at a younger age [26]. Simi-
larly, Mawak et  al. [28], found high prevalence among 
people who had their first sexual intercourse at ages 
between 15–19 years, but the difference was also not sig-
nificant (P = 0.147).
Table 5 continued
Characteristic Total Positive N (%) Statistics: χ2, P value OR, 95 % CI (odd ratio, 
95 % confidence interval)
Skin problem
 No 154 50 (32.5) χ2 = 0.082, P = 0.774 OR 0.921, 95 % CI 0.52–1.62
 Yes 88 27 (30.7)
Past skin problem
 No 167 54 (32.3) χ2 = 0.161, P = 0.688 OR 0.887, 95 % CI 0.48–1.60
 Yes 74 22 (29.7)
Table 6 Prevalence of chlamydia in relation to the sexual behavior of the participants
Variables Characteristics Total (N) Positive N (%) Statistics
Age at first sex 12–15 years 16 7 (43.8) χ2 = 0.691, P = 0.406, OR = 1.544, 95 % CI 0.551–4.327
16–18 years 108 42 (38.9) χ2 = 2.056, P = 0.152, OR = 1.511, 95 % CI 0.858–2.662
19–22 years 70 20 (28.6) χ2 = 3.633, P = 0.045, OR = 0.681, 95 % CI 0.367–1.264
23 years and above 16 5 (22) χ2 = 3.633, P = 0.057, OR = 0.254, 95 % CI 0.056–1.149
No of sex partners since first sex 1–4 sex partners 129 48 (37.2) χ2 = 0.889, P = 0.346, OR = 1.33, 95 % CI 0.73–2.427
5–9 sex partners 38 12 (31.6) χ2 = 0711, P = 0.646, OR = 0.838, 95 % CI 0.395–1.781
More than 10 partner 40 12 (30.0) χ2 = 0.500, P = 0.480, OR = 0.764, 95 % CI 0.362–1.612
No of sex partners the previous year 0 partners 64 20 (31.3) χ2 = 0.412, P = 0.521, OR = 0.815, 95 % CI 0.436–1.524
1 partner 114 44 (38.6) χ2 = 1.893, P = 0.169, OR = 1.496, 95 % CI 0.842–2.657
2–4 partners 27 7 (25.9) χ2 = 0.992, P = 0.319, OR = 0.631, 95 % CI 0.254–1.571
5 or more partners 7 2 (28.6) χ2 = 0.110, P = 0.740, OR = 0.755, 95 % CI 0.143–3.990
Condom use Always 84 24 (29.8) χ2 = 1.841, P = 0.175 OR = 0.605, 95 % CI 0.292–1.253
Never 13 4 (30.8) χ2 = 0.070, P = 0.791, OR = 0.847, 95 % CI 0.246–2.913
Sometimes 38 17 (44.7) χ2 = 2.677, P = 0.102, OR = 1.898, 95 % CI 0.876–4.113
Currently abstaining from sex No 46 46 (34.2) χ2 = 0.000, P = 0.988, OR = 1.005, 95 % CI 0.559–1.804
Yes 27 27 (34.1)
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People with multiple sexual partners in the previous year 
appeared to have more infection [27]. Although number 
of sexual partners has been found to be statistically associ-
ated with C. trachomatis infection in other studies, Mawak 
and his colleagues reported that 37.2  % of people with 
multiple sexual partners tested positive for chlamydia but 
the difference was not statistically significant [28]. In the 
present study a high prevalence was found among people 
who indicated that they had had only one sexual partner in 
the previous year (38.6 %). Verhoeven in 2012 reported a 
prevalence of 17.9 % in people who had more than 6 sexual 
partners in the previous year with the difference being sta-
tistically significant P = 0.000 [26]. In a population based 
survey in Estonia on the prevalence of chlamydia, the num-
ber of sexual partners in the past 12 months was the strong-
est predictor of the infection because participants with 2 or 
more partners had the highest prevalence (11.8  %) when 
compared to those with only one sex partner (3.8 %) and 
the difference was statistically significant (P = 0.002) [23].
Previous epidemiological studies reported that unpro-
tected sex was one of the major causes of sexually trans-
mitted infections and a modifiable risk factor. In 2012 
Dubbink and colleagues also reported a higher preva-
lence (40 %) in people who did not use condoms in the 
Mopani District South Africa [35]. In our study, a high 
prevalence was found in people who indicated that they 
use condoms sometimes (44.7 %) compared to those who 
said they use condoms always (33 %), however the differ-
ence was not statistically significant (P = 0.262). A preva-
lence of (4.41 %) in people who never use condoms was 
found in Cameroon [36]. Klovstad and colleagues [27] 
also reported a higher prevalence (10.1 %) among sexu-
ally active men who have unprotected sex.
In the present study we also looked at the potential 
associations between CT infections and other clinical 
characteristics that the patients had experienced such as 
genital warts, sores on genitals, sores on lips, rash on gen-
itals, mouth rash and history of other STD’s, associations 
with the infection were noted. A non-significant incidence 
of 7.5 % in people with genital warts has been previously 
reported [27]. Presence or history of other STD’s has also 
been identified as a risk factor for CT [29]. Similar out-
comes were obtained by Ngadjio and colleagues [36] who 
found that people who had history of other STI’s had 
6.19 % prevalence compared to 2.43 % among people who 
did not have other STI’s [34]. A previous study in Mpuma-
langa, South Africa on measuring the impact of HIV and 
STI’s in a community in a coal mining town, found a prev-
alence of 19 % in people who had a history of other STI’s. 
History of other STI’s was also reported as one of the risk 
factors for the chlamydia infection with 41.46  % which 
was statistically significant [28]. Other conditions such as 
pregnancy, history of abortion, miscarriage also appear 
to be in relation to the chlamydia infection. Mawak and 
colleagues reported on history of abortion (26.22 %) as a 
result of this infection [28].
Conclusions
In conclusion, the prevalence of Chlamydia was deter-
mined in HIV and AIDS patients in the Vhembe District. 
The prevalence was higher among young people and this 
emphasizes the need to enhance STI control among all 
young people. The use of ARV appeared to be beneficial 
in reducing the prevalence of chlamydia among HIV pos-
itive patients. However further studies are needed in the 
general population both HIV positive and HIV negative 
persons to further determine the impact of these infec-
tions in the community.
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